MBX (MBX Biosciences) Short-Term Debt : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Short-Term Debt?

MBX Biosciences's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

MBX Biosciences Short-Term Debt Historical Data

The historical data trend for MBX Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Short-Term Debt Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Short-Term Debt

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial			-	-	-	-	-

MBX Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

MBX Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.